Cifra broker published a quarterly review of Artgen Biotech

list

Analysts predict Artgen Biotech's revenue growth by more than 30% in 2025.

According to Cifra broker analysts, the dynamics of financial indicators reflect the growing profile of Artgen Biotech (MOEX: ABIO), and the company’s favorable prospects are justified by the expected increase in sales volumes of the blockbuster Neovasculgen and the emergence of 10 new drugs for the treatment of genetic, age-related, infectious and oncological diseases in the portfolio in the coming years as a part of the company's development strategy.

The report noted that over three years, the share of sales of Neovasculgen within the structure of the company’s total revenue has increased significantly: from 16% in 2021 to 33% in 2023. Also, active work is underway to expand the application scope of this drug.

Research is currently conducted on the use of Neovasculgen for the treatment of diabetic foot disease and interstitial cystitis. If this research is successful, the product could enter the market for the treatment of these diseases as early as 2026-2027.

The possibility to use Neovasculgen for androgenetic alopecia is also being considered. If the research results are successful, the drug may become available to a wide range of patients in 2028.

Conservative analyst estimates suggest sales growth for Neovasculgen by 27% in 2024 and also by 9% annually in 2025-2026.

Due to the expansion of the application scope of Neovasculgen, as well as the entry into the market of new Histograft products, such as Inject-Bone, Inject-Soft, 3D-Bone, Cover Bone, Supl-Bone, and the Onconetics test of Genetico, analysts at Cifra Broker predict revenue growth for Artgen Biotech by more than 30% in 2025.

Analysts expect the first significant revenues from the sale of vaccines to appear starting in 2025, instead of the previously expected revenue growth in 2024.

You can read the full version of the report here.